|
KMID : 1377020140110050350
|
|
Tissue Engineering and Regenerative Medicine
2014 Volume.11 No. 5 p.350 ~ p.354
|
|
|
Efficacy comparison of nanoniosomal and pegylated nanoniosomal Cisplatin on A172 cell line
|
|
Mahrokh Babaei
Mehdi Ardjmand
Azim Akbarzadeh
Aliakbar Seyfkordi
|
|
|
Abstract
|
|
|
|
In this study, Cisplatin was loaded into nanoniosom and pegylated nanoniosom employing reverse phase evaporation method. Span 60, cholesterol and Cisplatin were combined together at certain concentrations in this method. This study reports the efficacy of nanoniosome Cisplatin and pegylated nanoniosome Cisplatin on brain cancer (A172) cell line. All of the results are presented from three independent tests. The obtained results showed that the stability of prepared formulation was increased by pegylation. Encapsulation efficiency and loading efficiency of Cisplatin in pegylated and non-pegylated niosomal formulations were estimated 48.2±2.05%, 43.6±4.59%, 4.38±0.28%, 4.36±0.08%, respectively. The average diameters of pegylated and non-pegylated nanoparticles of niosomes were determined by Zeta sizer which was 205.5±4.60 nm and 242.1±5.10 nm, respectively. The release of drug was studied by dialysis method. The amounts of drug released from pegylated and non-pegylated nanoniosomes were calculated 82.73±1.36% and 97.53±0.55% during 48 hr, respectively. The toxicity of formulated Cisplatin was studied by MTT assay and the results revealed that the cytotoxicity effect of pegylated nanoniosomal Cisplatin was more than nanoniosomal Cisplatin. The IC50 for nanoniosomal Cisplatin was estimated 123.2±0.98 μg/mL while IC50 for pegylated nanoniosomal formulation was calculated 79.8±1.14 μg/mL.
|
|
|
KEYWORD
|
|
|
Nanoniosome, Cisplatin, MTT, A172, IC50
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
   
|